How to Trade SPDR S&P Biotech ETF (BIOTECH) on Hyperliquid

What Is the SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is a State Street fund launched in January 2006 that tracks the S&P Biotechnology Select Industry Index. With roughly $7.8 billion in assets and 151 holdings, it is one of the most widely traded biotech ETFs on the market.

The critical detail is the equal-weight methodology. Unlike the iShares Biotechnology ETF (IBB), where the top 10 holdings command over 50% of assets, XBI caps each position near 1-2% of the fund. That means a Phase 3 win at a $2 billion clinical-stage company moves the needle just as much as earnings from Amgen. The current top holdings — Moderna (2.3%), Roivant Sciences (1.8%), Arcellx (1.8%), Revolution Medicines (1.6%) — illustrate the breadth. You get exposure to gene therapy, cell therapy, oncology, vaccines, and rare disease all in one ticker.

The fund charges a 0.35% expense ratio and trades on NYSE Arca. Its 52-week range spans $66.66 to $132.09, reflecting the kind of volatility biotech traders either love or fear — often both.

Why BIOTECH Matters Right Now

Biotech is in the middle of a structural repricing. After years of post-COVID underperformance, XBI posted a 44% one-year return as of February 2026 and is up roughly 4.5% year-to-date. The rally has been broad-based, which is exactly the environment where an equal-weighted fund outperforms.

The biggest catalyst is the patent cliff. Over 200 drugs face patent expiration in the coming years, including 69 blockbusters generating more than $1 billion annually. Big Pharma is sitting on approximately $1 trillion in combined cash reserves and is spending aggressively to refill pipelines. In 2025 alone, M&A reached $49 billion — surpassing all of 2024 — with megadeals from Johnson & Johnson ($14.6B for Intra-Cellular Therapies), Merck (~$10B for Verona Pharma), and Sanofi ($9.1B for Blueprint Medicines).

That M&A wave is a direct tailwind for XBI's equal-weighted small and mid-cap constituents. Acquisition targets tend to be exactly the kind of companies XBI overweights relative to cap-weighted funds. Meanwhile, FDA approval rates remain strong and the therapeutic pipeline across obesity, Alzheimer's, genetic medicine, and oncology continues to deepen. Analysts at Truist Securities expect 2026 to be defined by strategic partnerships, margin stability, and innovation-led growth.

The HIP-3 Perpetual Contract

On Hyperliquid, BIOTECH trades as a HIP-3 perpetual futures contract deployed by Ventuals (vntl). The perp tracks XBI's spot price via an oracle feed, allowing traders to go long or short biotech exposure around the clock — no brokerage account, no market hours, no settlement delays.

The contract currently trades near $122.50 with daily volume around $205,000 and supports up to 20x leverage. Funding rates are periodic payments between longs and shorts that keep the perp price anchored to the underlying. When the perp trades above spot, longs pay shorts; when below, shorts pay longs. This is standard perpetual futures mechanics, but it matters here because biotech can gap hard on binary catalysts — an FDA decision or clinical data readout can move the underlying 5-10% in a session.

For position sizing, the relatively modest open interest means large orders can move the book. Traders should be aware of slippage on size and may want to scale in rather than market-buying a full position. The 20x max leverage is generous for a sector ETF this volatile — a 5% adverse move at 20x wipes the position. Most experienced perp traders will run 2-5x on a name like this unless they are day-trading a specific catalyst.

Key Trading Considerations

Binary event risk. Biotech is a catalyst-driven sector. FDA approval decisions, clinical trial data readouts, and M&A announcements can cause overnight gaps in XBI that the perp will reprice to reflect. Equal-weighting dampens single-stock impact, but sector-wide events — like a regulatory policy shift or a high-profile trial failure — still hit hard.

Correlation regime. During broad risk-off selloffs, biotech tends to correlate with growth equities. But during sector-specific rallies (M&A waves, FDA approval clusters), XBI can decouple from the S&P 500 entirely. Understanding which regime you are in matters for hedging and directional conviction.

Equal-weight rebalancing. XBI rebalances quarterly, which creates a mechanical buy-low, sell-high effect. After a constituent surges on a drug approval, it gets trimmed back to equal weight. After a drawdown, it gets topped up. This mean-reversion dynamic can be useful context for timing entries around rebalance dates.

Funding rate awareness. In a strong biotech bull market, the BIOTECH perp may trade at a premium to spot, meaning longs pay funding to shorts. Over time, this cost eats into leveraged long positions. Monitor the funding rate on Hyperliquid before entering and factor it into your expected holding cost.

Liquidity. With ~$205K in daily volume, this is not a deep market. Tight stops and large leveraged positions may not execute cleanly. Treat BIOTECH as a conviction position tool, not a scalping instrument.

Trading on Hyperliquid

Trade BIOTECH on Hyperliquid with up to 20x leverage.